The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors

P Krawczyk, DM Kowalski, K Wojas-Krawczyk, R Mlak… - Chemotherapy, 2012 - karger.com
Background: We evaluated the effectiveness of docetaxel or erlotinib in second-line
treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive …
被引用次数：21 相关文章

The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors.

P Krawczyk, DM Kowalski… - Chemotherapy …, 2012 - search.ebscohost.com
Background: We evaluated the effectiveness of docetaxel or erlotinib in second-line
treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive …

[引用][C] The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors

P Krawczyk, DM Kowalski, K Wojas-Krawczyk, R Mlak… - Chemotherapy, 2012 - cir.nii.ac.jp
The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on
Clinical and Molecular Predictive Factors | CiNii Research CiNii 国立情報学研究所 学術情報 …

The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors

P Krawczyk, DM Kowalski… - …, 2012 - pubmed.ncbi.nlm.nih.gov
Background We evaluated the effectiveness of docetaxel or erlotinib in second-line
treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive …

The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors

P Krawczyk, DM Kowalski, K Wojas-krawczyk… - …, 2012 - search.proquest.com
The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on
Clinical and Molecular Predictive Factors Page 1 Fax +41 61 306 12 34 E-Mail karger@karger.ch …
[PDF] researchgate.net

[PDF][PDF] The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors

P Krawczyk, DM Kowalski, K Wojas-Krawczyk… - …, 2012 - researchgate.net
Background: We evaluated the effectiveness of docetaxel or erlotinib in second-line
treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive …
[PDF] academia.edu

[PDF][PDF] The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors

P Krawczyk, DM Kowalski, K Wojas-Krawczyk… - …, 2012 - academia.edu
Background: We evaluated the effectiveness of docetaxel or erlotinib in second-line
treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive …

The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors

P Krawczyk, DM Kowalski, K Wojas-Krawczyk, R Mlak… - Chemotherapy, 2012 - karger.com
Background: We evaluated the effectiveness of docetaxel or erlotinib in second-line
treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive …

The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.

P Krawczyk, DM Kowalski, K Wojas-Krawczyk… - …, 2012 - europepmc.org
Background We evaluated the effectiveness of docetaxel or erlotinib in second-line
treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive …
[PDF] academia.edu

[PDF][PDF] The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors

P Krawczyk, DM Kowalski, K Wojas-Krawczyk… - …, 2012 - academia.edu
Background: We evaluated the effectiveness of docetaxel or erlotinib in second-line
treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive …